Rezolute reported a mixed clinical and corporate update: its Phase 3 SUNRIZE trial in congenital hyperinsulinism did not meet...

Beyond Air reported fiscal Q3 results with revenue up 105% year over year to $2.2 million, maintained full-year guidance...

CRISPR Therapeutics reported fourth-quarter and full-year 2025 results, spotlighting commercial traction for CASGEVY and a pipeline tilting from ex...

Biofrontera reported positive, statistically significant Phase 3 results for Ameluz photodynamic therapy using the RhodoLED platform in mild to...

PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, bringing full-year revenue...

Grace Therapeutics has a PDUFA date of April 23, 2026 for GTX-104, its intravenous formulation of nimodipine for aneurysmal...

Ocular Therapeutix will unveil topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related...

Neuronetics reported preliminary, unaudited fourth-quarter and full-year 2025 results showing material step-up in scale following its integration of Greenbrook...

PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, with full-year revenue...

Orchestra BioMed granted stock options covering 120,000 shares to nine new hires under its Nasdaq-compliant inducement plan, signaling a...